The Swiss blood products, vaccines and biological pharmaceuticals group Immuno AG increased sales in 1994 by 10% in local currency terms. Sales were 636 million Swiss francs ($563.8 million), up 2% when expressed in Swiss francs.
Gross profits advanced 3% to 369.8 million francs while net profits moved up 9.5% to 35.6 million francs. The company was affected by continuing declines in exchange rates of key export currencies, especially the Italian lira. Italy is Immuno's second largest export market and because of government controls, price increases could offset the fall in earnings only marginally.
Additional measures enhanced the security reserves of the biological drugs made by the company from human plasma. Only batches of products are being released for which genetic equivalents of the HIV, hepatitis B and hepatitis C virus have not been detected by means of the Immuno quality-assured polymerase chain-reaction (IQ-PCR) test.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze